Campbell & CO Investment Adviser LLC Purchases Shares of 23,516 Inhibrx, Inc. (NASDAQ:INBX)

Campbell & CO Investment Adviser LLC acquired a new position in shares of Inhibrx, Inc. (NASDAQ:INBXFree Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 23,516 shares of the company’s stock, valued at approximately $894,000.

Other institutional investors have also modified their holdings of the company. AJOVista LLC acquired a new stake in Inhibrx in the 4th quarter worth about $26,000. Quadrant Capital Group LLC acquired a new position in shares of Inhibrx in the 4th quarter valued at about $26,000. Signaturefd LLC raised its holdings in Inhibrx by 4,637.5% in the fourth quarter. Signaturefd LLC now owns 758 shares of the company’s stock valued at $29,000 after buying an additional 742 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Inhibrx by 389.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,471 shares of the company’s stock valued at $208,000 after acquiring an additional 4,354 shares during the period. Finally, Arizona State Retirement System acquired a new stake in Inhibrx in the 4th quarter valued at $209,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Stock Performance

Inhibrx stock opened at $16.89 on Thursday. The stock’s 50 day moving average price is $33.07 and its 200 day moving average price is $33.12. Inhibrx, Inc. has a one year low of $15.25 and a one year high of $18.95. The company has a debt-to-equity ratio of 17.68, a quick ratio of 3.82 and a current ratio of 3.82. The firm has a market capitalization of $885.07 million, a PE ratio of -3.36 and a beta of 2.87.

Insider Buying and Selling

In other news, insider Brendan P. Eckelman sold 300,000 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $34.30, for a total value of $10,290,000.00. Following the completion of the sale, the insider now owns 1,735,553 shares of the company’s stock, valued at approximately $59,529,467.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 22.20% of the company’s stock.

About Inhibrx

(Free Report)

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

Further Reading

Institutional Ownership by Quarter for Inhibrx (NASDAQ:INBX)

Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.